Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NantKwest
Biotech
2 Nants become one as Soon-Shiong merges NantKwest, ImmunityBio
NantKwest made a splash in 2015 with its $207 million IPO, but five years on, it’s becoming the vehicle for ImmunityBio to go public.
Amirah Al Idrus
Dec 21, 2020 10:23am
Soon-Shiong sued over Abraxane rival drug buy—Chutes & Ladders
Apr 5, 2019 9:30am
First data with NantKwest’s cancer vaccine ‘unclear’
Nov 12, 2018 10:40am
Soon-Shiong planning IPO for cancer vaccine subsidiary: report
Jun 11, 2018 10:20am
NantHealth cuts staff, offloads assets as Q2 losses hit $70M
Aug 11, 2017 7:53am
NantCell in $356M deal for underperforming CytRx cancer drug
Jul 28, 2017 9:47am
